Careram (iguratimod) / Eisai, R-Pharm 
Welcome,         Profile    Billing    Logout  
 7 Diseases   1 Trial   1 Trial   73 News 
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Preclinical, Journal:  Transfer and accumulation of antibiotic resistance genes and bacterial pathogens in the mice gut due to consumption of organic foods. (Pubmed Central) -  Feb 8, 2024   
    A total of 8 types of major ARGs and 10 mobile genetic elements (MGEs) were detected in mice gut, including tetracycline, multidrug, sulfonamide, aminoglycoside, beta-lactamase, chloramphenicol, MLSB and vancomycin resistance genes...Importantly, feeding organic food increased the relative abundance of the potentially antibiotic-resistant pathogens, Bacteroides and Streptococcus. Our results confirm that there is an increasing risk of ARGs and ARB in the gut microbiome, which highlights the importance of organic food industries taking into account the potential accumulation and transmission of ARGs as a risk factor.
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Trial completion, Trial completion date, Trial primary completion date:  The Efficacy and Safety of Tofacitinib (TF) With Iguratimod (IGU) on RA (clinicaltrials.gov) -  Nov 18, 2023   
    P4,  N=100, Completed, 
    Our results confirm that there is an increasing risk of ARGs and ARB in the gut microbiome, which highlights the importance of organic food industries taking into account the potential accumulation and transmission of ARGs as a risk factor. Recruiting --> Completed | Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Dec 2022 --> Jun 2023
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment (clinicaltrials.gov) -  Nov 18, 2023   
    P4,  N=400, Completed, 
    Recruiting --> Completed | Trial completion date: Dec 2022 --> Jul 2023 | Trial primary completion date: Dec 2022 --> Jun 2023 Active, not recruiting --> Completed | N=200 --> 400 | Trial completion date: Dec 2025 --> Oct 2023 | Trial primary completion date: Dec 2025 --> Sep 2023
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm, Humira (adalimumab) / Eisai, AbbVie
    New P4 trial, Immunomodulating:  The Clinical Efficacy of Immunomodulators in RA Patients (clinicaltrials.gov) -  Nov 23, 2022   
    P4,  N=400, Recruiting, 
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Trial completion date, Trial primary completion date:  The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment (clinicaltrials.gov) -  Sep 21, 2022   
    P4,  N=200, Active, not recruiting, 
    The compound microbial agent assisted the temperature rise of composting, thereby changing the related microbial community structure and resulting in ARGs/MGEs removal. Trial completion date: Dec 2021 --> Dec 2025 | Trial primary completion date: Dec 2021 --> Dec 2025
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Preclinical, Journal:  Nano-AlO particles affect gut microbiome and resistome in an in vitro simulator of the human colon microbial ecosystem. (Pubmed Central) -  Jul 27, 2022   
    This is attributed to that low concentration of nano-AlO can promote horizontal transfer of ARGs by increasing cell membrane permeability and relative abundance of transposase (e.g. tnpA, IS613, and Tp614). Our findings confirmed the adverse effects of nano-AlO on the human gut resistome and emphasized the necessity to assess potential risks of nanomaterials on the human gut health.
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Journal:  Iguratimod Inhibits Skin Fibrosis by regulating TGF-β1/Smad Signaling Pathway in Systemic Sclerosis. (Pubmed Central) -  Jul 15, 2022   
    Our findings confirmed the adverse effects of nano-AlO on the human gut resistome and emphasized the necessity to assess potential risks of nanomaterials on the human gut health. Our preliminary data indicated T-614 inhibited dermal fibroblasts activation and skin fibrosis at least partly by regulating TGF-β1/smad pathway in experimental SSc models and may be a promising therapeutic agent for SSc.
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Journal:  Antibiotic resistome and its driving factors in an urban river in northern China. (Pubmed Central) -  Jun 25, 2022   
    Moreover, random forest algorithm explored that WT, Ni, DO, Co, and polyether and macrolide antibiotics were the main drivers (>10 %) of ARGs dissemination in water, whereas the transposase genes of Tp614, tnpA, and IS613 were the main drivers of ARGs dissemination in both water and sediment. This study provides a comprehensive understanding of the driving factors for the ARGs dissemination in an urban river, which is of great significance for risk management of antibiotic resistome.
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Journal:  T-614 attenuates knee osteoarthritis via regulating Wnt/β-catenin signaling pathway. (Pubmed Central) -  Oct 28, 2021   
    The effectiveness of safety measures implemented during the all-case surveillance of iguratimod was evaluated, revealing that early implementation of safety measures decreased the incidence of adverse drug reactions. Our results suggested that T-614 can reduce the level of its downstream target gene MMP-13 and downregulate the expression of inflammatory cytokines TNF-α and IL-6 by regulating the Wnt/β-catenin signaling pathway, thereby inhibiting joint inflammation and controlling KOA degeneration of articular cartilage.
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Enrollment closed, Trial completion date, Trial primary completion date:  The Clinical Efficacy and Safety of Iguratimod in RA and Early RA Patients for 6 Months Treatment (clinicaltrials.gov) -  Aug 12, 2021   
    P4,  N=200, Active, not recruiting, 
    To cite this abstract in AMA style: Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Preclinical, Journal:  T-614 inhibits human aortic adventitial fibroblast proliferation and promotes interleukin-8 production in vitro. (Pubmed Central) -  Sep 16, 2020   
    Recruiting --> Active, not recruiting | Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2021 In the absence or presence of TNF-α, T-614 can inhibit HAAF proliferation and promote IL-8 production in vitro; therefore, it could be used to prevent adventitial thickening of the aorta and improve vascular remodeling in inflammatory environments in vitro and might provide a new immunotherapeutic intervention for TA.
  • ||||||||||  Iremod (iguratimod) / Simcere, Careram (iguratimod) - Eisai, R / Pharm
    Trial completion date, Trial primary completion date:  The Iguratimod Effect on Lupus Nephritis (IGeLU) (clinicaltrials.gov) -  Dec 20, 2018   
    P2,  N=120, Recruiting, 
    In conclusion, T-614 plays a protective role in experimental SAP mice model via anti-inflammatory effects. Trial completion date: Aug 2019 --> Nov 2021 | Trial primary completion date: Jan 2019 --> Nov 2020
  • ||||||||||  Iremod (iguratimod) / Simcere, Careram (iguratimod) - Eisai, R / Pharm
    Enrollment open, Trial initiation date:  The Iguratimod Effect on Lupus Nephritis (IGeLU) (clinicaltrials.gov) -  Nov 7, 2017   
    P2,  N=120, Recruiting, 
    Trial primary completion date: Mar 2018 --> Jun 2018 Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Sep 2017
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    New P1/2 trial:  Study of Iguratimod in Sjögren's Syndrome (clinicaltrials.gov) -  Jan 18, 2017   
    P1/2,  N=30, Recruiting, 
  • ||||||||||  Careram (iguratimod) - Eisai, R / Pharm
    Trial completion, Enrollment change, Trial primary completion date:  Investigation of the Safety and Efficacy of Iguratimod in Patients With Rheumatoid Arthritis (clinicaltrials.gov) -  Dec 30, 2016   
    P=N/A,  N=2747, Completed, 
    Not yet recruiting --> Recruiting | Initiation date: Mar 2017 --> Sep 2017 Recruiting --> Completed | N=1108 --> 2747 | Trial primary completion date: Dec 2016 --> Apr 2014
  • ||||||||||  Iremod (iguratimod) / Simcere, Careram (iguratimod) - Eisai, R / Pharm
    New P2 trial:  The Iguratimod Effect on Lupus Nephritis (IGeLU) (clinicaltrials.gov) -  Oct 18, 2016   
    P2,  N=120, Not yet recruiting,